However, while agents that target the WNT pathway remain in development, the availability of BRAF inhibitors such as vemurafenib and dabrafenib has proven effective in reducing the tumor size in patients with papillary craniopharyngiomas [17,18,19]. The gene discussed is BRAF; the disease is neoplasm.